Article

Evaluation of multiple serum markers in advanced melanoma.

Laboratory of Biochemistry, University Clinic of Navarra, Avd. Pio XII 36, Pamplona, 31008, Spain.
Tumor Biology (impact factor: 1.94). 08/2011; 32(6):1155-61. DOI:10.1007/s13277-011-0218-x pp.1155-61
Source: PubMed

ABSTRACT The aim of this retrospective study was to analyse in advanced melanoma the potential tumor markers S-100B, melanoma inhibiting activity protein (MIA) and YKL-40 compared to LDH. Serum levels of S-100B, MIA, LDH and YKL-40 were measured in 110 patients with advanced melanoma (36 in stage IIIB/C and 74 in stage IV), in 66 disease-free patients and in 65 healthy controls. Results show that S-100B, MIA and LDH levels were significantly higher in patients with advanced melanoma than in disease-free patients or healthy controls. The combination of S-100B plus MIA had the best diagnostic sensitivity, and the addition of LDH did not further increase this sensitivity. MIA was an independent prognostic factor of overall survival. Patients with both S-100B and MIA elevated had a significant shorter survival than those with both S-100B and MIA under the cut-off. YKL-40 levels did not differentiate patients with advanced melanoma from controls. We concluded that the combination of MIA plus S-100B showed a better prognostic value in advanced melanoma compared to LDH.

0 0
 · 
0 Bookmarks
 · 
37 Views
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.

Keywords

65 healthy controls
 
66 disease-free patients
 
analyse
 
cut-off
 
diagnostic sensitivity
 
disease-free patients
 
healthy controls
 
independent prognostic factor
 
LDH
 
LDH levels
 
melanoma inhibiting activity protein
 
MIA
 
patients
 
potential tumor markers S-100B
 
retrospective study
 
Serum levels
 
significant shorter survival
 
stage IIIB/C
 
stage IV
 
YKL-40 levels